8049 Cisplatin-based combination chemotherapy (CTX) consisting of docetaxel and cisplatin (DP) is still effective for patients with relapsed ovarian carcinoma (ROC) resistant or refractory to carboplatin-based CTX (TC: taxol/carboplatin)

Y.Shimizu; F.Murakami; N.Saitoh; A.Yamasaki; N.Ogawa; T.Ishiya; K.Katase; S.Sakurai

首页> 外文期刊>European Journal of Cancer Supplements >8049 Cisplatin-based combination chemotherapy (CTX) consisting of docetaxel and cisplatin (DP) is still effective for patients with relapsed ovarian carcinoma (ROC) resistant or refractory to carboplatin-based CTX (TC: taxol/carboplatin)

【24h】

8049 Cisplatin-based combination chemotherapy (CTX) consisting of docetaxel and cisplatin (DP) is still effective for patients with relapsed ovarian carcinoma (ROC) resistant or refractory to carboplatin-based CTX (TC: taxol/carboplatin)

机译：8049由多西他赛和顺铂（DP）组成的基于顺铂的联合化疗（CTX）对于复发性卵巢癌（ROC）耐药或难治性基于卡铂的CTX（TC：紫杉醇/卡铂）的患者仍然有效

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
Y.Shimizu; F.Murakami; N.Saitoh; A.Yamasaki; N.Ogawa; T.Ishiya; K.Katase; S.Sakurai;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. 8049 Cisplatin-based combination chemotherapy (CTX) consisting of docetaxel and cisplatin (DP) is still effective for patients with relapsed ovarian carcinoma (ROC) resistant or refractory to carboplatin-based CTX (TC: taxol/carboplatin) [J] . Y.Shimizu, F.Murakami, N.Saitoh, European Journal of Cancer Supplements . 2009,第2期

机译：8049由多西他赛和顺铂（DP）组成的基于顺铂的联合化疗（CTX）对于复发性卵巢癌（ROC）耐药或难治性基于卡铂的CTX（TC：紫杉醇/卡铂）的患者仍然有效
2. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer [J] . Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第1期

机译：一项II期随机研究评估了铂类敏感性卵巢癌复发患者中基于卡铂的化学疗法与帕妥珠单抗联合单独使用基于卡铂的疗法的组合
3. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study) [J] . UedaY., MiyatakeT., NagamatsuM., European Journal of Obstetrics, Gynecology and Reproductive Biology: An International Journal . 2013,第1期

机译：使用多西紫杉醇和伊立替康联合化疗的II期临床研究，用于TC难治性或TC耐药性卵巢癌（GOGO-OV2研究）和原发性透明或粘液性卵巢癌（GOGO-OV3研究）
4. A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN) [O] . Jian Guan, Qinyang Li, Yue Zhang, 2016

机译：荟萃分析比较中晚期头颈鳞癌（SCCHN）中基于顺铂和基于卡铂的化疗
5. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? [O] . Rachana Shah, Caihong Xia, Mark Krailo, 2018

机译：基于卡铂的化疗是基于顺铂的化疗的有效治疗儿童，青少年和年轻成年人的晚期脱节剂吗？

8049 Cisplatin-based combination chemotherapy (CTX) consisting of docetaxel and cisplatin (DP) is still effective for patients with relapsed ovarian carcinoma (ROC) resistant or refractory to carboplatin-based CTX (TC: taxol/carboplatin)

著录项

相似文献

相关主题

期刊订阅